"Nevermind" is apparently in order.
Yesterday's reports that Onyx had shared clinical trial data for its European phase III trial with Kyprolis were apparently greatly exaggerated. That is to say 'were full of it'.
Today's story is that Amgen didn't get the data it wanted to cement its $130 per share offer and now is moving backward in the price it wants to pay to acquire Onyx. Remember Onyx already turned down a $120 per share offer as being undervalued.
Where does that leave us? I dunno. But it seems to me that an acquisition of Onyx by Amgen, or any of the other mythical suitors, is becoming increasingly unlikely (or will be prolonged dance). Onyx shareholders shouldn't spend their projected 50% premium checks just yet. See Bloomberg.
Posed by Bruce Lehr Aug 23rd 2013.